Background: Weight management strategies are central to the control and remission of type 2 diabetes (T2D). Yet, scalable interventions remain elusive. We report the real-world outcomes of a scalable, digitally-enabled lifestyle program utilizing diabetes-specific nutrition formula (DSNF) as part of a low-calorie diet for people with obesity and T2D.
Methods: 185 adult participants with recently diagnosed T2D and 27 ≤BMI≤ 45 kg/m2 were recruited from 28 primary care practices (Newcastle upon Tyne, UK). The 12-week weight loss phase included the use of a DSNF (Glucerna®, Abbott) as part of a low-calorie diet (900-1000 kcal/day). The diet was personalized, allowing use of Glucerna® for meal replacement, real food, or a combination of both. Anti-hyperglycemic medication was withdrawn while clinical care remained with the primary clinicians. Behavioral coaching was offered digitally alongside educational content, interactive quizzes, and diet planners.
Results: Participants (55±9 years, 53% male, 70% White) engaged well with the digital service, with 78% (n=145) completing the weight loss phase. Content engagement was high (average 360 minutes content read; 60 minutes 1:1 coaching across five sessions); Glucerna® adherence was >80%. A significant 10% weight loss reduction (-10 kg [95%CI: -12, -8]) and ~1% HbA1c reduction (10.9 mmol/mol [95%CI: -11,-7]) were reported at 3 months. Significant reduction in blood pressure was also reported (p-values<0.01). No significant differences were observed between intent-to-treat and evaluable cohorts.
Conclusions: A remote, digitally-enabled lifestyle program using a DSNF as part of a low-calorie diet significantly improved body weight and diabetes control in people with obesity and T2D.
M. Trenell: Consultant; Changing Health, Abbott Nutrition. L.C. Taylor: Employee; Changing Health Ltd. K.W. Kerr: Employee; Abbott. Stock/Shareholder; Abbott. R. Rueda: Employee; Abbott Nutrition. S. Sulo: Employee; Abbott Nutrition.
Financial support for this study was provided by Abbott and UK Research and Innovation.